View Older Stories View More Recent Stories

Mar 26, 2020 04:32PM Translate Bio (TBIO) announces FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis
Mar 26, 2020 04:30PM Translate Bio Provides MRT5005 Program Updates
Mar 26, 2020 04:30PM Translate Bio Provides MRT5005 Program Updates
Mar 12, 2020 04:45PM Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
Mar 12, 2020 04:45PM Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
Feb 26, 2020 07:39AM Translate Bio (TBIO) Receives FDA Fast Track Designation for MRT5005 for Treatment of Cystic Fibrosis
Feb 26, 2020 07:30AM Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
Feb 26, 2020 07:30AM Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
Feb 19, 2020 07:30AM Translate Bio to Present at Upcoming Investor Conferences
Feb 19, 2020 07:30AM Translate Bio to Present at Upcoming Investor Conferences
Dec 12, 2019 04:29PM Translate Bio (TBIO) Announces Executive Leadership Appointments
Dec 12, 2019 04:15PM Translate Bio Announces Executive Leadership Appointments
Dec 12, 2019 04:15PM Translate Bio Announces Executive Leadership Appointments
Nov 13, 2019 07:30AM Translate Bio to Present at Upcoming Investor Conferences
Nov 13, 2019 07:30AM Translate Bio to Present at Upcoming Investor Conferences
Nov 6, 2019 04:11PM Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights
Nov 6, 2019 04:11PM Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights
Oct 31, 2019 12:17PM Translate Bio (TBIO) Bio Presents MRT5005 Data at NACFC
Oct 31, 2019 12:15PM Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference
Oct 31, 2019 12:15PM Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference
Oct 1, 2019 07:30AM Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
Oct 1, 2019 07:30AM Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
Sep 30, 2019 07:30AM Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
Sep 30, 2019 07:30AM Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
Sep 12, 2019 04:05PM Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
Sep 12, 2019 04:05PM Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
Sep 9, 2019 05:02PM Translate Bio (TBIO) Announces Pipeline Program Update, Prioritizing Development of Pulmonary Disease Programs
Sep 9, 2019 04:05PM Translate Bio Announces Pipeline Program Update
Sep 9, 2019 04:05PM Translate Bio Announces Pipeline Program Update
Jul 31, 2019 06:57AM Translate Bio (TBIO) Reports Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
Jul 31, 2019 06:51AM Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31, 2019 06:51AM Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31, 2019 06:50AM Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
Jul 31, 2019 06:50AM Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
Jul 15, 2019 07:34AM Translate Bio (TBIO) Names George Demetri MD to Board
Jul 15, 2019 07:30AM Translate Bio Appoints George Demetri, M.D., to its Board of Directors
Jul 15, 2019 07:30AM Translate Bio Appoints George Demetri, M.D., to its Board of Directors
Jun 26, 2019 07:04AM Translate Bio (TBIO) Announces FDA Clearance to Proceed with Single-ascending Dose Phase 1/2 Clinical Trial for OTC Deficiency
Jun 26, 2019 07:00AM Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
Jun 26, 2019 07:00AM Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
May 28, 2019 07:30AM Translate Bio to Present at the Jefferies 2019 Healthcare Conference
May 28, 2019 07:30AM Translate Bio to Present at the Jefferies 2019 Healthcare Conference
May 9, 2019 04:23PM Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 9, 2019 04:23PM Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
Apr 29, 2019 08:45AM Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Apr 29, 2019 08:45AM Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Apr 11, 2019 07:39AM Translate Bio (TBIO) Names Robert Plenge, M.D., Ph.D. to Board
Apr 11, 2019 07:30AM Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors
Apr 8, 2019 04:05PM Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting
Apr 8, 2019 04:05PM Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting
View More Recent Stories View Older Stories